Abstract Number: 1132 • 2017 ACR/ARHP Annual Meeting
Compensated Polarized Microscopy for Crystal Identification Shows High Reliability Among Multiple Observers
Background/Purpose: The gold standard for crystal-related arthritis diagnosis remains synovial fluid analysis by a microscope fitted with compensated polarized filters as it has been shown…Abstract Number: 1133 • 2017 ACR/ARHP Annual Meeting
Are We Ready? Changes in the Profile of Gout Patients over the Last 25 Years
Background/Purpose: Gout is a rising cause of hospital admissions and emergency consults. It has even replaced rheumatoid arthritis as the principal rheumatological condition causing hospitalizations. Some…Abstract Number: 1134 • 2017 ACR/ARHP Annual Meeting
A Case Series of Gout and Downs Syndrome – a New Paradigm for Detecting Disease Associations Using Big Data
Background/Purpose: Down syndrome (Trisomy 21) is known to have higher prevalence of certain conditions including cardiac defects, hypothyroidism, hearing defects and early Alzheimer’s disease, but…Abstract Number: 1135 • 2017 ACR/ARHP Annual Meeting
the Incidence of Knee Chondrocalcinosis and Its Risk Factors in Community-Based Cohort
Background/Purpose: Chondrocalcinosis (CC) results from deposition of calcium pyrophosphate dihydrate (CPPD) in articular cartilage. It is a relatively common radiographic finding of the joints, especially…Abstract Number: 1136 • 2017 ACR/ARHP Annual Meeting
Urate-Lowering Treatment and Risk of Total Joint Replacement in Patients with Incident Gout: A Population-Based Cohort and Nested Case-Control Study
Background/Purpose: This cohort study aimed to investigate the risk of total joint (hip/knee) replacement (TJR, THR and TKR) among patients with incident gout at initial…Abstract Number: 1137 • 2017 ACR/ARHP Annual Meeting
Urate Lowering to ACR-Recommended Targets Allows Significant Improvement of Severe Gout: A Monocentric Prospective Trial in Vietnam, Using a Systematic Treatment Protocol
Background/Purpose: Gout is frequent and severe in Vietnam, where urate-lowering drugs (ULD) are seldom used and many patients are treated only with traditional herbal medicine.…Abstract Number: 1138 • 2017 ACR/ARHP Annual Meeting
Investigation on Allele Frequency of Rs3117583 and Rs9263726 in Patients with Hyperuricemia or Gout
Background/Purpose: Allopurinol, effectively regulates and controls serum uric acid levels but may cause allopurinol-induced life-threating severe cutaneous adverse reaction (SCAR). Previous studies reported that single…Abstract Number: 1139 • 2017 ACR/ARHP Annual Meeting
Management of Gout – a Survey for Healthcare Providers in South Australia
Background/Purpose: Gout is a treatable arthritis and while the rate of gout in Australia has been steadily rising, drugs used to treat acute gouty arthritis…Abstract Number: 1140 • 2017 ACR/ARHP Annual Meeting
Gout Characteristics and Its Association with the Presence of Cardiovascular Disease: A Case-Control Study
Background/Purpose: Gout is an independent risk factor for any type of cardiovascular disease (CVD). The exact mechanism behind remains to be elucidated, but persistent crystal-related…Abstract Number: 1141 • 2017 ACR/ARHP Annual Meeting
Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate
Background/Purpose: Pegloticase is a pegylated recombinant mammalian uricase approved for treatment of persons with chronic gout refractory to standard urate lowering therapy1. Despite initial reduction…Abstract Number: 1142 • 2017 ACR/ARHP Annual Meeting
A Case Control Study of Anakinra Use for Acute Gout in a VA Patient Cohort Reveals Association with East Asian Descent, High Urate Burden, and Increased Co-Morbidities and All-Cause Mortality
Background/Purpose: Effectiveness of the IL-1 receptor antagonist anakinra, in resolving flares of acute gout, has been reported in several case series. Here, studying a VA…Abstract Number: 1143 • 2017 ACR/ARHP Annual Meeting
The Patient Education for Gout Patients Ameliorate the Patients’ Satisfaction and Serum Uric Acid Level
Background/Purpose: The poor adherence to urate lowering therapy is due to a lack of appropriate information. This study performed to analyze the effect of education…Abstract Number: 1144 • 2017 ACR/ARHP Annual Meeting
Initiating Colchicine and Urate-Lowering Therapy Reduces Baseline Inflammation, and Improves Vascular Endothelial but Not Smooth Muscle Function in Gout Subjects: Resistance to Endothelial Improvement Among Patients with Cardiovascular Comorbidities
Background/Purpose: We have previously reported that patients with gout have impaired vascular endothelial and smooth muscle responsiveness, but whether initiating appropriate gout therapy ameliorates these…Abstract Number: 1145 • 2017 ACR/ARHP Annual Meeting
Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals
Background/Purpose: The concept of a multidisciplinary gout clinic is relatively new in Singapore. Changi General Hospital launched such a clinic in 2014 to provide treat-to-target…Abstract Number: 1146 • 2017 ACR/ARHP Annual Meeting
Associations between Gout and Cancer in an Nhanes Cohort
Background/Purpose: Gout is the most common inflammatory disease in the United States (US), affecting more than 4% of the population. Although uric acid (UA) can…
ACR Meeting Abstracts